Aspirin

CHICAGO — In patients who had PCI with a drug-eluting stent, dual antiplatelet therapy with indobufen plus clopidogrel was noninferior to DAPT with aspirin plus clopidogrel, according to the results of the OPTION trial.

After a minor stroke or transient ischemic attack, patients with normal vs. impaired renal function treated with ticagrelor plus aspirin had lower risk for stroke at 90 days compared with clopidogrel plus aspirin, researchers reported.

For adults who undergo PCI with a drug-eluting stent, recommendations for dual antiplatelet therapy have evolved from a standard 1-year duration for most patients to a more nuanced approach that balances risks for ischemia and bleeding.

Among patients with chronic kidney disease, aspirin use did not correlate with reduced risks for CVD, progression to kidney failure or major bleeding, according to data published in Kidney Medicine.

GENEVA — Women who used low-dose aspirin did not exhibit reduced risk for breast cancer, according to study results presented at World Cancer Congress.

In a large cohort of patients with spontaneous coronary artery dissection, the rates of mortality and recurrent spontaneous coronary artery dissection were low at 3 years, researchers reported.

TAMPA, Fla. —Aspirin as a thromboprophylaxis agent was noninferior to low-molecular-weight heparin for all-cause mortality in patients with extremity, pelvic or acetabular fractures, presented results showed.

Older adults with elevated lipoprotein(a)-associated genotypes may benefit from low-dose aspirin for primary prevention of cardiovascular events, according to researchers.

Healio and Cardiology Today have aggregated a list of the most-read news in cardiology of September 2022.

Low-dose aspirin for primary prevention of CV events may benefit older adults with elevated lipoprotein(a)-associated genotypes, according to a new analysis of the ASPREE trial.